NCT00085124 - Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2007

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

BIOLOGICAL

oblimersen sodium

Given IV

DRUG

cytarabine

Given IV

DRUG

daunorubicin hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH